메뉴 건너뛰기




Volumn 10, Issue 9, 2014, Pages 531-542

Advances in the management of psoriatic arthritis

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; APREMILAST; BRAZIKUMAB; BRODALUMAB; CERTOLIZUMAB PEGOL; CLAZAKIZUMAB; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; IXEKIZUMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB;

EID: 84908085446     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.106     Document Type: Review
Times cited : (70)

References (126)
  • 1
    • 14244260176 scopus 로고    scopus 로고
    • Psoriatic arthritis: Epidemiology, clinical features, course, and outcome
    • Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O. & Nash, P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64, (Suppl. 2), ii14-ii17 (2005).
    • (2005) Ann. Rheum. Dis. , vol.64 , pp. ii14-ii17
    • Gladman, D.D.1    Antoni, C.2    Mease, P.3    Clegg, D.O.4    Nash, P.5
  • 2
    • 0034023936 scopus 로고    scopus 로고
    • Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms
    • Scarpa, R. et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J. Rheumatol. 27, 1241-1246 (2000).
    • (2000) J. Rheumatol. , vol.27 , pp. 1241-1246
    • Scarpa, R.1
  • 3
    • 0036178901 scopus 로고    scopus 로고
    • Clinical features and predictive factors in psoriatic arthritis-related uveitis
    • Queiro, R. et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin. Arthritis Rheum. 31, 264-270 (2002).
    • (2002) Semin. Arthritis Rheum. , vol.31 , pp. 264-270
    • Queiro, R.1
  • 4
    • 33750400902 scopus 로고    scopus 로고
    • Metabolic disorders in patients with psoriasis and psoriatic arthritis
    • Mallbris, L., Ritchlin, C. T. & Ståhle, M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep. 8, 355-363 (2006).
    • (2006) Curr. Rheumatol. Rep. , vol.8 , pp. 355-363
    • Mallbris, L.1    Ritchlin, C.T.2    Ståhle, M.3
  • 5
    • 32144445910 scopus 로고    scopus 로고
    • Psoriasis psoriatic arthritis, or psoriatic disease?
    • Scarpa, R., Ayala, F., Caporaso, N. & Olivieri, I. Psoriasis, psoriatic arthritis, or psoriatic disease? J. Rheumatol. 33, 210-212 (2006).
    • (2006) J. Rheumatol. , vol.33 , pp. 210-212
    • Scarpa, R.1    Ayala, F.2    Caporaso, N.3    Olivieri, I.4
  • 6
    • 67449128733 scopus 로고    scopus 로고
    • The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection
    • Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann. Rheum. Dis. 68, 777-783 (2009).
    • (2009) Ann. Rheum. Dis. , vol.68 , pp. 777-783
    • Rudwaleit, M.1
  • 7
    • 78650679234 scopus 로고    scopus 로고
    • The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
    • Rudwaleit, M. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70, 25-31 (2011).
    • (2011) Ann. Rheum. Dis. , vol.70 , pp. 25-31
    • Rudwaleit, M.1
  • 8
    • 0038603010 scopus 로고    scopus 로고
    • Progression of peripheral joint disease in psoriatic arthritis
    • McHugh, N. J., Balachrishnan, C. & Jones, S. M. Progression of peripheral joint disease in psoriatic arthritis. Rheumatology (Oxford) 42, 778-783 (2003).
    • (2003) Rheumatology (Oxford) , vol.42 , pp. 778-783
    • McHugh, N.J.1    Balachrishnan, C.2    Jones, S.M.3
  • 10
    • 0025800559 scopus 로고
    • Psoriatic arthritis (PA): A clinical, immunological and radiological study of 180 patients
    • Torre-Alonso, J. C. et al. Psoriatic arthritis (PA): A clinical, immunological and radiological study of 180 patients. Br. J. Rheumatol. 30, 245-250 (1991).
    • (1991) Br. J. Rheumatol. , vol.30 , pp. 245-250
    • Torre-Alonso, J.C.1
  • 11
    • 0030767275 scopus 로고    scopus 로고
    • Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death
    • Wong, K., Gladman, D. D., Husted, J., Long, J.A. & Farewell, V. T. Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 40, 1868-1872 (1997).
    • (1997) Arthritis Rheum. , vol.40 , pp. 1868-1872
    • Wong, K.1    Gladman, D.D.2    Husted, J.3    Long, J.A.4    Farewell, V.T.5
  • 12
    • 0031802067 scopus 로고    scopus 로고
    • Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death
    • Gladman, D. D., Farewell, V. T., Wong, K. & Husted, J. Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 41, 1103-1110 (1998).
    • (1998) Arthritis Rheum. , vol.41 , pp. 1103-1110
    • Gladman, D.D.1    Farewell, V.T.2    Wong, K.3    Husted, J.4
  • 13
    • 33745782642 scopus 로고    scopus 로고
    • Disability and quality of life considerations. Psoriatic arthritis
    • (eds Gordon, G. B. & Ruderman, E.) (Springer-Verlag, Heidelberg
    • Gladman, D. D. Disability and quality of life considerations. Psoriatic arthritis. In Psoriasis and Psoriatic Arthritis: An Integrated Approach (eds Gordon, G. B. & Ruderman, E.) 118-123 (Springer-Verlag, Heidelberg 2005).
    • (2005) Psoriasis and Psoriatic Arthritis: An Integrated Approach , pp. 118-123
    • Gladman, D.D.1
  • 14
    • 37749019317 scopus 로고    scopus 로고
    • Lower limbs enthesopathy in patients with psoriasis without clinical signs of arthropathy: An hospital-based case-control study
    • Gisondi, P. et al. Lower limbs enthesopathy in patients with psoriasis without clinical signs of arthropathy: An hospital-based case-control study. Ann. Rheum. Dis. 67, 26-30 (2008).
    • (2008) Ann. Rheum. Dis. , vol.67 , pp. 26-30
    • Gisondi, P.1
  • 15
    • 77955488365 scopus 로고    scopus 로고
    • Beyond early diagnosis: Occult psoriatic arthritis
    • Palazzi, C., Lubrano, E., D'Angelo, S. & Olivieri, I. Beyond early diagnosis: Occult psoriatic arthritis. J. Rheumatol. 37, 1556-1558 (2010).
    • (2010) J. Rheumatol. , vol.37 , pp. 1556-1558
    • Palazzi, C.1    Lubrano, E.2    D'Angelo, S.3    Olivieri, I.4
  • 16
    • 64849094127 scopus 로고    scopus 로고
    • Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis
    • Reich, K., Kruger, K., Mossner, R. & Augustin, M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br. J. Dermatol. 160, 1040-1047 (2009).
    • (2009) Br. J. Dermatol. , vol.160 , pp. 1040-1047
    • Reich, K.1    Kruger, K.2    Mossner, R.3    Augustin, M.4
  • 17
    • 77950795910 scopus 로고    scopus 로고
    • The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics
    • Christophers, E. et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J. Eur. Acad. Dermatol. Venereol. 24, 548-554 (2010).
    • (2010) J. Eur. Acad. Dermatol. Venereol. , vol.24 , pp. 548-554
    • Christophers, E.1
  • 18
    • 84875956855 scopus 로고    scopus 로고
    • High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires
    • Haroon, M., Kirby, B. & FitzGerald, O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann. Rheum. Dis. 72, 736-740 (2013).
    • (2013) Ann. Rheum. Dis. , vol.72 , pp. 736-740
    • Haroon, M.1    Kirby, B.2    FitzGerald, O.3
  • 19
    • 34548538646 scopus 로고    scopus 로고
    • The PASE questionnaire: Pilot-testing a psoriatic arthritis screening and evaluation tool
    • Husni, M. E., Meyer, K. H., Cohen, D. S., Mody, E. & Qureshi, A. A. The PASE questionnaire: Pilot-testing a psoriatic arthritis screening and evaluation tool. J. Am. Acad. Dermatol. 57, 581-587 (2007).
    • (2007) J. Am. Acad. Dermatol. , vol.57 , pp. 581-587
    • Husni, M.E.1    Meyer, K.H.2    Cohen, D.S.3    Mody, E.4    Qureshi, A.A.5
  • 20
    • 69049097129 scopus 로고    scopus 로고
    • Validity reliability, and sensitivity-to change properties of the psoriatic arthritis screening and evaluation questionnaire
    • Dominguez, P. L., Husni, M. E., Holt, E. W., Tyler, S. & Qureshi, A. Validity, reliability, and sensitivity-to change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch. Dermatol. Res. 301, 573-579 (2009).
    • (2009) Arch. Dermatol. Res. , vol.301 , pp. 573-579
    • Dominguez, P.L.1    Husni, M.E.2    Holt, E.W.3    Tyler, S.4    Qureshi, A.5
  • 21
    • 65249091381 scopus 로고    scopus 로고
    • Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS)
    • Gladman, D. D. et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS). Ann. Rheum. Dis. 68, 497-501 (2009).
    • (2009) Ann. Rheum. Dis. , vol.68 , pp. 497-501
    • Gladman, D.D.1
  • 23
    • 67651171603 scopus 로고    scopus 로고
    • Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: The Psoriasis Epidemiology Screening Tool (PEST) questionnaire
    • Ibrahim, G. H., Buch, M. H., Lawson, C., Waxman, R. & Helliwell, P. S. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: The Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin. Exp. Rheumatol. 27, 469-474 (2009).
    • (2009) Clin. Exp. Rheumatol. , vol.27 , pp. 469-474
    • Ibrahim, G.H.1    Buch, M.H.2    Lawson, C.3    Waxman, R.4    Helliwell, P.S.5
  • 24
    • 79956048725 scopus 로고    scopus 로고
    • The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): A sensitive and specific tool to diagnose psoriatic arthritis patients
    • Khraishi, M., Mong, J., Mugford, G. & Landells, I. The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): A sensitive and specific tool to diagnose psoriatic arthritis patients. J. Cutan. Med. Surg. 15, 143-149 (2011).
    • (2011) J. Cutan. Med. Surg. , vol.15 , pp. 143-149
    • Khraishi, M.1    Mong, J.2    Mugford, G.3    Landells, I.4
  • 25
    • 84867820789 scopus 로고    scopus 로고
    • The early psoriatic arthritis screening questionnarie: A simple and fast method for the identification of arthritis in patients with psoriasis
    • Tinazzi, I. et al. The early psoriatic arthritis screening questionnarie: A simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology 51, 2058-2063 (2012).
    • (2012) Rheumatology , vol.51 , pp. 2058-2063
    • Tinazzi, I.1
  • 26
    • 84875429609 scopus 로고    scopus 로고
    • Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)
    • Coates, L. C. et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br. J. Dermatol. 168, 802-807 (2013).
    • (2013) Br. J. Dermatol. , vol.168 , pp. 802-807
    • Coates, L.C.1
  • 27
    • 84874851329 scopus 로고    scopus 로고
    • Limitations in screening instruments for psoriatic arthritis: A comparison of instruments in patients with psoriasis
    • Walsh, J. A., Callin Duffin, K., Krueger, G. G. & Clegg, D. O. Limitations in screening instruments for psoriatic arthritis: A comparison of instruments in patients with psoriasis. J. Rheumatol. 40, 287-293 (2013).
    • (2013) J. Rheumatol. , vol.40 , pp. 287-293
    • Walsh, J.A.1    Callin Duffin, K.2    Krueger, G.G.3    Clegg, D.O.4
  • 28
    • 33746951437 scopus 로고    scopus 로고
    • Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
    • Taylor, W. et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 54, 2665-2673 (2006).
    • (2006) Arthritis Rheum. , vol.54 , pp. 2665-2673
    • Taylor, W.1
  • 29
    • 84863838231 scopus 로고    scopus 로고
    • Performance of classification criteria for peripheral spondyloarthrtis and psoriatic arthritis in the Leiden Early Arthritis cohort
    • van der Berg, R., van Gaalen, F., van der Helm-van Mil, A., Huizinga, T. & van der Heijde, D. Performance of classification criteria for peripheral spondyloarthrtis and psoriatic arthritis in the Leiden Early Arthritis cohort. Ann. Rheum. Dis. 71, 1366-1369 (2012).
    • (2012) Ann. Rheum. Dis. , vol.71 , pp. 1366-1369
    • Van Der Berg, R.1    Van Gaalen, F.2    Van Der Helm-Van Mil, A.3    Huizinga, T.4    Van Der Heijde, D.5
  • 30
    • 84862499025 scopus 로고    scopus 로고
    • Classification and clinical assessment
    • Marchesoni, A. & Cantini, F. Classification and clinical assessment. Reumatismo 64, 79-87 (2012).
    • (2012) Reumatismo , vol.64 , pp. 79-87
    • Marchesoni, A.1    Cantini, F.2
  • 31
    • 37349081288 scopus 로고    scopus 로고
    • Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis
    • Chandran, V., Schentag, C. T. & Gladman, D. D. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 57, 1560-1563 (2007).
    • (2007) Arthritis Rheum. , vol.57 , pp. 1560-1563
    • Chandran, V.1    Schentag, C.T.2    Gladman, D.D.3
  • 32
    • 64849104327 scopus 로고    scopus 로고
    • Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis
    • D'Angelo, S. et al. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J. Rheumatol. 36, 368-370 (2009).
    • (2009) J. Rheumatol. , vol.36 , pp. 368-370
    • D'Angelo, S.1
  • 33
    • 84869030520 scopus 로고    scopus 로고
    • Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis
    • Coates, L. C. et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 64, 3150-3155 (2012).
    • (2012) Arthritis Rheum. , vol.64 , pp. 3150-3155
    • Coates, L.C.1
  • 34
    • 58149394480 scopus 로고    scopus 로고
    • Can we identify psoriatic arthritis early?
    • Gladman, D. D. Can we identify psoriatic arthritis early? Curr. Rheumatol. Rep. 10, 419-421 (2008).
    • (2008) Curr. Rheumatol. Rep. , vol.10 , pp. 419-421
    • Gladman, D.D.1
  • 36
    • 70350746171 scopus 로고    scopus 로고
    • The diagnosis and treatment of early psoriatic arthritis
    • Anandarajah, A. P. & Ritchlin, C. T. The diagnosis and treatment of early psoriatic arthritis. Nat. Rev. Rheumatol. 5, 634-641 (2009).
    • (2009) Nat. Rev. Rheumatol. , vol.5 , pp. 634-641
    • Anandarajah, A.P.1    Ritchlin, C.T.2
  • 37
    • 77950307115 scopus 로고    scopus 로고
    • Treating rheumatoid arthritis to target: Recommendations of an international task force
    • Smolen, J. S. et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637 (2010).
    • (2010) Ann. Rheum. Dis. , vol.69 , pp. 631-637
    • Smolen, J.S.1
  • 38
    • 77950309959 scopus 로고    scopus 로고
    • Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search
    • Shoels, M. et al. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search. Ann. Rheum. Dis. 69, 638-643 (2010).
    • (2010) Ann. Rheum. Dis. , vol.69 , pp. 638-643
    • Shoels, M.1
  • 39
    • 84889634412 scopus 로고    scopus 로고
    • Targeting spondyloarthtitis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force
    • Smolen, J. S. et al. Targeting spondyloarthtitis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force. Ann. Rheum. Dis. 73, 6-16 (2014).
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 6-16
    • Smolen, J.S.1
  • 40
    • 84889683977 scopus 로고    scopus 로고
    • Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: Results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
    • Schoels, M. M. et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: Results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann. Rheum. Dis. 73, 238-242 (2014).
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 238-242
    • Schoels, M.M.1
  • 41
    • 73449100479 scopus 로고    scopus 로고
    • Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment
    • Coates, L. C., Fransen, J. & Helliwell, P. S. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann. Rheum. Dis. 69, 48-53 (2010).
    • (2010) Ann. Rheum. Dis. , vol.69 , pp. 48-53
    • Coates, L.C.1    Fransen, J.2    Helliwell, P.S.3
  • 42
    • 0037233923 scopus 로고    scopus 로고
    • Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patient with early rheumatoid arthritis
    • Conaghan, P. G. et al. Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patient with early rheumatoid arthritis. Arthritis Rheum. 48, 64-71 (2003).
    • (2003) Arthritis Rheum. , vol.48 , pp. 64-71
    • Conaghan, P.G.1
  • 43
    • 3242677099 scopus 로고    scopus 로고
    • Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomized controlled study
    • Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomized controlled study. Lancet 364, 263-269 (2004).
    • (2004) Lancet , vol.364 , pp. 263-269
    • Grigor, C.1
  • 44
    • 0032722907 scopus 로고    scopus 로고
    • Progression in psoriatic arthritis: Role of time varying clinical indicators
    • Gladman, D. D. & Farewell, V. T. Progression in psoriatic arthritis: Role of time varying clinical indicators. J. Rheumatol. 26, 2409-2413 (1999).
    • (1999) J. Rheumatol. , vol.26 , pp. 2409-2413
    • Gladman, D.D.1    Farewell, V.T.2
  • 45
    • 34147208743 scopus 로고    scopus 로고
    • Predictors for radiological damage in psoriatic arthritis: Results from a single centre
    • Bond, S. J., Farewell, V. T., Schentag, C. T. & Gladman, D. D. Predictors for radiological damage in psoriatic arthritis: Results from a single centre. Ann. Rheum. Dis. 66, 370-376 (2007).
    • (2007) Ann. Rheum. Dis. , vol.66 , pp. 370-376
    • Bond, S.J.1    Farewell, V.T.2    Schentag, C.T.3    Gladman, D.D.4
  • 46
    • 84875181495 scopus 로고    scopus 로고
    • The TICOPA protocol (tight control of psoriatic arthritis): A randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis
    • Coates, L. C. et al. The TICOPA protocol (tight control of psoriatic arthritis): A randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet. Disord. 14, 101 (2013).
    • (2013) BMC Musculoskelet. Disord. , vol.14 , pp. 101
    • Coates, L.C.1
  • 47
    • 84912126983 scopus 로고    scopus 로고
    • Results of a randomized controlled trial comparing tight control of early psoriatic arthrtis (TICOPA) with standard care: Tight control improves outcome [abstract]
    • Coates, L. C. et al. Results of a randomized controlled trial comparing tight control of early psoriatic arthrtis (TICOPA) with standard care: Tight control improves outcome [abstract]. Arthritis Rheum. 65, a814 (2013).
    • (2013) Arthritis Rheum. , vol.65 , pp. a814
    • Coates, L.C.1
  • 48
    • 82955236087 scopus 로고    scopus 로고
    • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
    • Gossec, L. et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann. Rheum. Dis. 71, 4-12 (2012).
    • (2012) Ann. Rheum. Dis. , vol.71 , pp. 4-12
    • Gossec, L.1
  • 49
    • 69949125952 scopus 로고    scopus 로고
    • Treatment recommendations for psoriatic arthritis
    • Ritchlin, C. T. et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis. 68, 1387-1394 (2009).
    • (2009) Ann. Rheum. Dis. , vol.68 , pp. 1387-1394
    • Ritchlin, C.T.1
  • 50
    • 36849016433 scopus 로고    scopus 로고
    • Recommendations of the French Society for Rheumatology regarding TNFa antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update
    • Pham, T. et al. Recommendations of the French Society for Rheumatology regarding TNFa antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74, 638-646 (2007).
    • (2007) Joint Bone Spine , vol.74 , pp. 638-646
    • Pham, T.1
  • 51
    • 80055095434 scopus 로고    scopus 로고
    • Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: Update from the Italian Society for Rheumatology
    • Salvarani, C. et al. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: Update from the Italian Society for Rheumatology. Clin. Exp. Rheumatol. 29, (Suppl. 66), S28-S41 (2011).
    • (2011) Clin. Exp. Rheumatol. , vol.29 , pp. S28-S41
    • Salvarani, C.1
  • 52
    • 79953770834 scopus 로고    scopus 로고
    • Consensus statement of the Spanish society of Rheumatology on the management of biologic therapies in psoriatic arthritis
    • Fernández Sueiro, J. L. et al. Consensus statement of the Spanish society of Rheumatology on the management of biologic therapies in psoriatic arthritis. Rheumatol. Clin. 7, 179-188 (2011).
    • (2011) Rheumatol. Clin. , vol.7 , pp. 179-188
    • Fernández Sueiro, J.L.1
  • 53
    • 84862996511 scopus 로고    scopus 로고
    • 2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis
    • Machado, P. et al. 2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis. Acta Rheumatol. Port. 37, 26-39 (2012).
    • (2012) Acta Rheumatol. Port. , vol.37 , pp. 26-39
    • Machado, P.1
  • 54
    • 84887539435 scopus 로고    scopus 로고
    • The 2012 BSR and BHPR guidelines for the treatment of psoriatic arthritis with biologics
    • Coates, L. C. et al. The 2012 BSR and BHPR guidelines for the treatment of psoriatic arthritis with biologics. Rheumatology 52, 1754-1757 (2013).
    • (2013) Rheumatology , vol.52 , pp. 1754-1757
    • Coates, L.C.1
  • 55
    • 80855151628 scopus 로고    scopus 로고
    • Measures of psoriatic arthritis: Tender and swollen joint assessment, psoriasis area and severity index (PASI)
    • Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)
    • Mease, P. J. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. (Hoboken) 63, (Suppl. 11) S64-S85 (2011).
    • (2011) Arthritis Care Res. (Hoboken) , vol.63 , pp. S64-S85
    • Mease, P.J.1
  • 56
    • 34248665535 scopus 로고    scopus 로고
    • Consensus on a core set of domains for psoriatic arthritis
    • Gladman, D. D. et al. Consensus on a core set of domains for psoriatic arthritis. J. Rheumatol. 34, 1167-1170 (2007).
    • (2007) J. Rheumatol. , vol.34 , pp. 1167-1170
    • Gladman, D.D.1
  • 57
    • 77949456275 scopus 로고    scopus 로고
    • Evaluation of the appropriateness for composite disease activity measures for assessment of psoriatic arthritis
    • Nell-Duxneuner, V. P. et al. Evaluation of the appropriateness for composite disease activity measures for assessment of psoriatic arthritis. Ann. Rheum. Dis. 69, 546-549 (2010).
    • (2010) Ann. Rheum. Dis. , vol.69 , pp. 546-549
    • Nell-Duxneuner, V.P.1
  • 58
    • 77955459298 scopus 로고    scopus 로고
    • Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis
    • Schoels, M. et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann. Rheum. Dis. 69, 1441-1447 (2010).
    • (2010) Ann. Rheum. Dis. , vol.69 , pp. 1441-1447
    • Schoels, M.1
  • 59
    • 78751701276 scopus 로고    scopus 로고
    • Development of a preliminary composite disease activity index in psoriatic arthritis
    • Mumtaz, A. et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann. Rheum. Dis. 70, 272-277 (2011).
    • (2011) Ann. Rheum. Dis. , vol.70 , pp. 272-277
    • Mumtaz, A.1
  • 60
    • 79952372121 scopus 로고    scopus 로고
    • Composite measures in psoriatic arthritis: A report from the GRAPPA 2009 annual meeting
    • Helliwell, P. S., Fitzgerald, O., Strand, C. V. & Mease, P. J. Composite measures in psoriatic arthritis: A report from the GRAPPA 2009 annual meeting. J. Rheumatol. 38, 540-545 (2011).
    • (2011) J. Rheumatol. , vol.38 , pp. 540-545
    • Helliwell, P.S.1    Fitzgerald, O.2    Strand, C.V.3    Mease, P.J.4
  • 61
    • 84877636515 scopus 로고    scopus 로고
    • The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
    • Helliwell, P. S. et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann. Rheum. Dis. 72, 986-991 (2013).
    • (2013) Ann. Rheum. Dis. , vol.72 , pp. 986-991
    • Helliwell, P.S.1
  • 62
    • 0017261080 scopus 로고
    • A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease
    • Lassus, A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease. Curr. Med. Res. Opin. 4, 65-69 (1976).
    • (1976) Curr. Med. Res. Opin. , vol.4 , pp. 65-69
    • Lassus, A.1
  • 63
    • 0020075974 scopus 로고
    • The run-in period in trial design: A comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy
    • Leatham, P. A., Bird, H. A., Wright, V. & Fowler, P. D. The run-in period in trial design: A comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy. Agents Actions 12, 221-224 (1982).
    • (1982) Agents Actions , vol.12 , pp. 221-224
    • Leatham, P.A.1    Bird, H.A.2    Wright, V.3    Fowler, P.D.4
  • 64
    • 0035065835 scopus 로고    scopus 로고
    • The role of NSAIDs in psoriatic arthritis: Evidence from a controlled study with nimesulide
    • Sarzi-Puttini, P., Santandrea, S., Boccassini, L., Panni, B. & Caruso, I. The role of NSAIDs in psoriatic arthritis: Evidence from a controlled study with nimesulide. Clin. Exp. Rheumatol. 19 (1 Suppl. 22), S17-S20 (2001).
    • (2001) Clin. Exp. Rheumatol. , vol.19 , Issue.1 , pp. S17-S20
    • Sarzi-Puttini, P.1    Santandrea, S.2    Boccassini, L.3    Panni, B.4    Caruso, I.5
  • 65
    • 36348982256 scopus 로고    scopus 로고
    • A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis
    • Kivitz, A. J., Espinoza, L. R., Sherrer, Y. R., Liu-Dumaw, M. & West, C. R. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin. Arthritis Rheum. 37, 164-173 (2007).
    • (2007) Semin. Arthritis Rheum. , vol.37 , pp. 164-173
    • Kivitz, A.J.1    Espinoza, L.R.2    Sherrer, Y.R.3    Liu-Dumaw, M.4    West, C.R.5
  • 66
    • 81155125087 scopus 로고    scopus 로고
    • Glucocorticoid treatment in spondyloarthritis
    • Fendler, C., Baraliakos, X. & Braun, J. Glucocorticoid treatment in spondyloarthritis. Clin. Exp. Rheumatol. 29, (5 Suppl. 68), S139-S142 (2011).
    • (2011) Clin. Exp. Rheumatol. , vol.29 , Issue.5 , pp. S139-S142
    • Fendler, C.1    Baraliakos, X.2    Braun, J.3
  • 67
    • 77954212051 scopus 로고    scopus 로고
    • Predictors of response to intra-articular steroid injection in psoriatic arthritis
    • Eder, L. et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 49, 1367-1373 (2010).
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 1367-1373
    • Eder, L.1
  • 68
    • 78650529461 scopus 로고    scopus 로고
    • Use of methotrexate in patients with psoriatic arthritis
    • Ceponis, A. & Kavanaugh, A. Use of methotrexate in patients with psoriatic arthritis. Clin. Exp. Rheumatol. 28, (5 Suppl. 61), S132-S137 (2010).
    • (2010) Clin. Exp. Rheumatol. , vol.28 , Issue.5 , pp. S132-S137
    • Ceponis, A.1    Kavanaugh, A.2
  • 69
    • 0028909238 scopus 로고
    • Longterm methotrexate therapy in psoriatic arthritis: Clinical and radiological outcome
    • Abu-Shakra, M. et al. Longterm methotrexate therapy in psoriatic arthritis: Clinical and radiological outcome. J. Rheumatol. 22, 241-245 (1995).
    • (1995) J. Rheumatol. , vol.22 , pp. 241-245
    • Abu-Shakra, M.1
  • 70
    • 40649111400 scopus 로고    scopus 로고
    • Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort
    • Chandran, V., Schentag, C. T. & Gladman, D. D. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort. J. Rheumatol. 35, 469-471 (2008).
    • (2008) J. Rheumatol. , vol.35 , pp. 469-471
    • Chandran, V.1    Schentag, C.T.2    Gladman, D.D.3
  • 71
    • 84865186509 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
    • Kingsley, G. H. et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51, 1368-1377 (2012).
    • (2012) Rheumatology (Oxford) , vol.51 , pp. 1368-1377
    • Kingsley, G.H.1
  • 72
    • 84860568139 scopus 로고    scopus 로고
    • Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?
    • Mease, P. J. Spondyloarthritis: Is methotrexate effective in psoriatic arthritis? Nat. Rev. Rheumatol. 8, 251-252 (2012).
    • (2012) Nat. Rev. Rheumatol. , vol.8 , pp. 251-252
    • Mease, P.J.1
  • 73
    • 0034790695 scopus 로고    scopus 로고
    • A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis
    • Salvarani, C. et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J. Rheumatol. 28, 2274-2282 (2001).
    • (2001) J. Rheumatol. , vol.28 , pp. 2274-2282
    • Salvarani, C.1
  • 74
    • 0036217529 scopus 로고    scopus 로고
    • Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis
    • Sarzi-Puttini, P. et al. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol. Int. 21, 234-238 (2002).
    • (2002) Rheumatol. Int. , vol.21 , pp. 234-238
    • Sarzi-Puttini, P.1
  • 75
    • 21144451096 scopus 로고    scopus 로고
    • A randomized double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis
    • Fraser, A. D. et al. A randomized double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann. Rheum. Dis. 64, 859-864 (2005).
    • (2005) Ann. Rheum. Dis. , vol.64 , pp. 859-864
    • Fraser, A.D.1
  • 76
    • 84876308124 scopus 로고    scopus 로고
    • Leflunomide in psoriatic arthritis: Results from a large European prospective observational study
    • Behrens, F. et al. Leflunomide in psoriatic arthritis: Results from a large European prospective observational study. Arthritis Care Res. (Hoboken) 65, 464-470 (2013).
    • (2013) Arthritis Care Res. (Hoboken) , vol.65 , pp. 464-470
    • Behrens, F.1
  • 77
    • 2642558895 scopus 로고    scopus 로고
    • Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial
    • Kaltwasser, J. P. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 50, 1939-1950 (2004).
    • (2004) Arthritis Rheum. , vol.50 , pp. 1939-1950
    • Kaltwasser, J.P.1
  • 78
    • 84886728119 scopus 로고    scopus 로고
    • Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate
    • Sakellariou, G. T., Sayegh, F.E, Anastasilakis, A. D. & Kapetanos, G. A. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol. Int. 33, 2917-2920 (2013).
    • (2013) Rheumatol. Int. , vol.33 , pp. 2917-2920
    • Sakellariou, G.T.1    Sayegh, F.E.2    Anastasilakis, A.D.3    Kapetanos, G.A.4
  • 79
    • 0033511186 scopus 로고    scopus 로고
    • Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study
    • Clegg, D. O., Reda, D. J. & Abdellatif, M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study. Arthritis Rheum. 42, 2325-2329 (1999).
    • (1999) Arthritis Rheum. , vol.42 , pp. 2325-2329
    • Clegg, D.O.1    Reda, D.J.2    Abdellatif, M.3
  • 80
    • 0029054947 scopus 로고
    • Sulfasalazine therapy for psoriatic arthritis: A double blind, placebo controlled trial
    • Gupta, A. K. et al. Sulfasalazine therapy for psoriatic arthritis: A double blind, placebo controlled trial. J. Rheumatol. 22, 894-898 (1995).
    • (1995) J. Rheumatol. , vol.22 , pp. 894-898
    • Gupta, A.K.1
  • 81
    • 0031752214 scopus 로고    scopus 로고
    • The use of sulfasalazine in psoriatic arthritis: A clinic experience
    • Rahman, P., Gladman, D. D., Cook, R. J., Zhou, Y. & Young, G. The use of sulfasalazine in psoriatic arthritis: A clinic experience. J. Rheumatol. 25, 1957-1961 (1998).
    • (1998) J. Rheumatol. , vol.25 , pp. 1957-1961
    • Rahman, P.1    Gladman, D.D.2    Cook, R.J.3    Zhou, Y.4    Young, G.5
  • 82
    • 84862487609 scopus 로고    scopus 로고
    • Psoriatic arthritis: Treatment strategies using biologic agents
    • D'Angelo, S., Palazzi, C. & Olivieri, I. Psoriatic arthritis: Treatment strategies using biologic agents. Reumatismo 64, 113-121 (2012).
    • (2012) Reumatismo , vol.64 , pp. 113-121
    • D'Angelo, S.1    Palazzi, C.2    Olivieri, I.3
  • 83
    • 84881650385 scopus 로고    scopus 로고
    • Psoriatic arthritis: Current therapy and future directions
    • Huynh, D. & Kavanaugh, A. Psoriatic arthritis: Current therapy and future directions. Expert Opin. Pharmacother. 14, 1755-1764 (2013).
    • (2013) Expert Opin. Pharmacother. , vol.14 , pp. 1755-1764
    • Huynh, D.1    Kavanaugh, A.2
  • 84
    • 84889668023 scopus 로고    scopus 로고
    • Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
    • Mease, P. J. et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis. 73, 48-55 (2014).
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 48-55
    • Mease, P.J.1
  • 85
    • 84891744277 scopus 로고    scopus 로고
    • Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: A systematic review and meta-analysis of randomised controlled trials
    • Goulabchand, R. et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: A systematic review and meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 73, 414-419 (2014).
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 414-419
    • Goulabchand, R.1
  • 86
    • 77950860194 scopus 로고    scopus 로고
    • Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs
    • Atteno, M. et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin. Rheumatol. 29, 399-403 (2010).
    • (2010) Clin. Rheumatol. , vol.29 , pp. 399-403
    • Atteno, M.1
  • 87
    • 84879994854 scopus 로고    scopus 로고
    • Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
    • Fénix-Caballero, S. et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J. Clin. Pharm. Ther. 38, 286-293 (2013).
    • (2013) J. Clin. Pharm. Ther. , vol.38 , pp. 286-293
    • Fénix-Caballero, S.1
  • 88
    • 84872245667 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: An indirect comparison meta-analysis
    • Thorlund, K., Druyts, E., Aviña-Zubieta, J. A. & Mills, E. J. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: An indirect comparison meta-analysis. Biologics 6, 417-427 (2012).
    • (2012) Biologics , vol.6 , pp. 417-427
    • Thorlund, K.1    Druyts, E.2    Aviña-Zubieta, J.A.3    Mills, E.J.4
  • 89
    • 84885182023 scopus 로고    scopus 로고
    • Switching between TNF inhibitors in psoriatic arthritis: Data from the NOR-DMARD study
    • Fagerli, K. M. et al. Switching between TNF inhibitors in psoriatic arthritis: Data from the NOR-DMARD study. Ann. Rheum. Dis. 72, 1840-1844 (2013).
    • (2013) Ann. Rheum. Dis. , vol.72 , pp. 1840-1844
    • Fagerli, K.M.1
  • 90
    • 84876572244 scopus 로고    scopus 로고
    • Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor a inhibitor therapy: Results from the Danish Nationwide DANBIO Registry
    • Glintborg, B. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor a inhibitor therapy: Results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 65, 1213-1223 (2013).
    • (2013) Arthritis Rheum. , vol.65 , pp. 1213-1223
    • Glintborg, B.1
  • 91
    • 84862499912 scopus 로고    scopus 로고
    • Pharmacoeconomic issues in psoriatic arthritis
    • Olivieri, I. et al. Pharmacoeconomic issues in psoriatic arthritis. J. Rheumatol. Suppl. 89, 103-105 (2012).
    • (2012) J. Rheumatol. Suppl. , vol.89 , pp. 103-105
    • Olivieri, I.1
  • 93
    • 0345099477 scopus 로고    scopus 로고
    • A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience
    • Kane, D., Stafford, L., Bresnihan, B. & FitzGerald, O. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford) 42, 1460-1468 (2003).
    • (2003) Rheumatology (Oxford) , vol.42 , pp. 1460-1468
    • Kane, D.1    Stafford, L.2    Bresnihan, B.3    FitzGerald, O.4
  • 94
    • 77952261781 scopus 로고    scopus 로고
    • Remission in psoriatic arthritis: Is it possible and how can it be predicted?
    • Saber, T. P. et al. Remission in psoriatic arthritis: Is it possible and how can it be predicted? Arthritis Res. Ther. 12, R94 (2010).
    • (2010) Arthritis Res. Ther. , vol.12 , pp. R94
    • Saber, T.P.1
  • 95
    • 44849131003 scopus 로고    scopus 로고
    • Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs
    • Cantini, F. et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 47, 872-876 (2008).
    • (2008) Rheumatology (Oxford) , vol.47 , pp. 872-876
    • Cantini, F.1
  • 96
    • 84866754677 scopus 로고    scopus 로고
    • Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study
    • Cantini, F., Niccoli, L., Cassarà, E., Kaloudi, O. & Nannini, C. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study. Biologics 6, 201-206 (2012).
    • (2012) Biologics , vol.6 , pp. 201-206
    • Cantini, F.1    Niccoli, L.2    Cassarà, E.3    Kaloudi, O.4    Nannini, C.5
  • 97
    • 84877823834 scopus 로고    scopus 로고
    • Can we reduce the dosage of biologics in spondyloarthritis?
    • Olivieri, I. et al. Can. we reduce the dosage of biologics in spondyloarthritis? Autoimmun. Rev. 12, 691-693 (2013).
    • (2013) Autoimmun. Rev. , vol.12 , pp. 691-693
    • Olivieri, I.1
  • 98
    • 84883134297 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    • McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780-789 (2013).
    • (2013) Lancet , vol.382 , pp. 780-789
    • McInnes, I.B.1
  • 99
    • 84873581440 scopus 로고    scopus 로고
    • Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a phase 3 multicenter, double-blind, placebo controlled-study
    • Ritchlin, C. et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a phase 3 multicenter, double-blind, placebo controlled-study. Arthritis Rheum. 64, S1080-S1081 (2012).
    • (2012) Arthritis Rheum. , vol.64 , pp. S1080-S1081
    • Ritchlin, C.1
  • 100
    • 84892170359 scopus 로고    scopus 로고
    • Ustekinumab associated with flares of psoriatic arthritis
    • Stamell, E. F., Kutner, A., Viola, K. & Cohen, S. R. Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol. 149, 1410-1413 (2013).
    • (2013) JAMA Dermatol. , vol.149 , pp. 1410-1413
    • Stamell, E.F.1    Kutner, A.2    Viola, K.3    Cohen, S.R.4
  • 101
    • 84872847067 scopus 로고    scopus 로고
    • Inflammatory arthritis following ustekinumab treatment for psoriasis: A report of two cases
    • de Souza, A., Ali-Shaw, T., Reddy, S. M., Fiorentino, D. & Strober, B. E. Inflammatory arthritis following ustekinumab treatment for psoriasis: A report of two cases. Br. J. Dermatol. 168, 210-212 (2013).
    • (2013) Br. J. Dermatol. , vol.168 , pp. 210-212
    • De Souza, A.1    Ali-Shaw, T.2    Reddy, S.M.3    Fiorentino, D.4    Strober, B.E.5
  • 102
    • 84876292569 scopus 로고    scopus 로고
    • Effect of IL-17A blockade with secukinumab in autoimmune diseases
    • Patel, D. D., Lee, D. M., Kolbinger, F. & Antoni, C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72 (Suppl. 2) ii116-ii123 (2013).
    • (2013) Ann. Rheum. Dis. , vol.72 , pp. ii116-ii123
    • Patel, D.D.1    Lee, D.M.2    Kolbinger, F.3    Antoni, C.4
  • 103
    • 84902209516 scopus 로고    scopus 로고
    • Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis
    • Mease, P.J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 12, 2295-2306 (2014).
    • (2014) N. Engl. J. Med. , vol.12 , pp. 2295-2306
    • Mease, P.J.1
  • 104
    • 84873168729 scopus 로고    scopus 로고
    • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study
    • Rich, P. et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br. J. Dermatol. 168, 402-411 (2013).
    • (2013) Br. J. Dermatol. , vol.168 , pp. 402-411
    • Rich, P.1
  • 105
    • 84891740105 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
    • McInnes, I. B. et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 73, 349-356 (2014).
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 349-356
    • McInnes, I.B.1
  • 106
    • 84988017945 scopus 로고    scopus 로고
    • US National Library of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/show/NCT01695239 (2014).
    • (2014) ClinicalTrials.gov [online]
  • 107
    • 84896129404 scopus 로고    scopus 로고
    • Clinical response to brodalumab, an anti-interleukin-17 receptor antibody, in subjects with psoriatic arthritis
    • Genovese, M. C. et al. Clinical response to brodalumab, an anti-interleukin-17 receptor antibody, in subjects with psoriatic arthritis. Arthritis Rheum. 65 (Suppl. 10), S347-S348 (2013).
    • (2013) Arthritis Rheum. , vol.65 , pp. S347-S348
    • Genovese, M.C.1
  • 108
    • 84923115890 scopus 로고    scopus 로고
    • Improvement in psoriasis symptoms and physical functioning with secukinumab compared with placebo and etanercept in subjects with moderate-to-severe plaque psoriasis and psoriatic arthritis: Results of a subanalysis from the phase 3 Fixture study
    • Gottlieb, A. et al. Improvement in psoriasis symptoms and physical functioning with secukinumab compared with placebo and etanercept in subjects with moderate-to-severe plaque psoriasis and psoriatic arthritis: Results of a subanalysis from the phase 3 Fixture study. Arthritis Rheum. 65, 3322 (2013).
    • (2013) Arthritis Rheum. , vol.65 , pp. 3322
    • Gottlieb, A.1
  • 109
    • 84860175869 scopus 로고    scopus 로고
    • Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
    • Schafer, P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem. Pharmacol. 83, 1583-1590 (2012).
    • (2012) Biochem. Pharmacol. , vol.83 , pp. 1583-1590
    • Schafer, P.1
  • 110
    • 84869014252 scopus 로고    scopus 로고
    • Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
    • Schett, G. et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 64, 3156-3167 (2012).
    • (2012) Arthritis Rheum. , vol.64 , pp. 3156-3167
    • Schett, G.1
  • 111
    • 84894898491 scopus 로고    scopus 로고
    • Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results of a phase 3, randomized, controlled trial
    • Kavanaugh, A. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results of a phase 3, randomized, controlled trial. Arthritis Rheum. 64, 4172-4173 (2012).
    • (2012) Arthritis Rheum. , vol.64 , pp. 4172-4173
    • Kavanaugh, A.1
  • 112
    • 84901833481 scopus 로고    scopus 로고
    • Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2)
    • Cutolo, M. et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). Arthritis Rheum. 65 (Suppl. 10), S346 (2013).
    • (2013) Arthritis Rheum. , vol.65 , pp. S346
    • Cutolo, M.1
  • 113
    • 84901833481 scopus 로고    scopus 로고
    • Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3)
    • Edwards, C. J. et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3). Arthritis Rheum. 65 (Suppl. 10), S132 (2013).
    • (2013) Arthritis Rheum. , vol.65 , pp. S132
    • Edwards, C.J.1
  • 114
    • 84901851651 scopus 로고    scopus 로고
    • Apremilast in the treatment of DMARD-naive psoriatic arthritis patients: Results of a phase 3 randomized, controlled trial (PALACE 4)
    • Wells, A. F. et al. Apremilast in the treatment of DMARD-naive psoriatic arthritis patients: Results of a phase 3 randomized, controlled trial (PALACE 4). Arthritis Rheum. 65, 3320-3321 (2013).
    • (2013) Arthritis Rheum. , vol.65 , pp. 3320-3321
    • Wells, A.F.1
  • 115
    • 79953701653 scopus 로고    scopus 로고
    • Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial
    • Mease, P. et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 63, 939-948 (2011).
    • (2011) Arthritis Rheum. , vol.63 , pp. 939-948
    • Mease, P.1
  • 116
    • 85029132794 scopus 로고    scopus 로고
    • Long-term 52-week results of PALACE 1, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase inhibitor, in patients with psoriatic arthritis
    • Adebajo, A. O. et al. Long-term 52-week results of PALACE 1, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase inhibitor, in patients with psoriatic arthritis. Rheumatology 53 (Suppl. 1), i141 (2014).
    • (2014) Rheumatology , vol.53 , pp. i141
    • Adebajo, A.O.1
  • 117
    • 84867401161 scopus 로고    scopus 로고
    • Rituximab in psoriatic arthritis: An exploratory evaluation
    • Jimenez-Boj, E. et al. Rituximab in psoriatic arthritis: An exploratory evaluation. Ann. Rheum. Dis. 71, 1868-1871 (2012).
    • (2012) Ann. Rheum. Dis. , vol.71 , pp. 1868-1871
    • Jimenez-Boj, E.1
  • 118
    • 79958809486 scopus 로고    scopus 로고
    • Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions
    • Mease, P. et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions. Arthritis Rheum. 62 (Suppl. 10), S818 (2010).
    • (2010) Arthritis Rheum. , vol.62 , pp. S818
    • Mease, P.1
  • 119
    • 84988017945 scopus 로고    scopus 로고
    • US National Library of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/show/NCT01860976 (2014).
    • (2014) ClinicalTrials.gov [online]
  • 120
    • 84870318190 scopus 로고    scopus 로고
    • Rituximab treatment for spondyloarthritis. A nationwide series: Data from the AIR registry of the French Society of Rheumatology
    • Wendling, D. et al. Rituximab treatment for spondyloarthritis. A nationwide series: Data from the AIR registry of the French Society of Rheumatology. J. Rheumatol. 39, 2327-2331 (2012).
    • (2012) J. Rheumatol. , vol.39 , pp. 2327-2331
    • Wendling, D.1
  • 121
    • 84882992107 scopus 로고    scopus 로고
    • Succesful use of tocilizumab in a patient with psoriatic arthritis
    • Hughes, M. & Chinoy, H. Succesful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology 52, 1728-1729 (2013).
    • (2013) Rheumatology , vol.52 , pp. 1728-1729
    • Hughes, M.1    Chinoy, H.2
  • 122
    • 84855716888 scopus 로고    scopus 로고
    • Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab
    • Ogata, A., Umegaki, N., Katayama, I., Kumanogoh, A., Tanaka, T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 79, 85-87 (2012).
    • (2012) Joint Bone Spine , vol.79 , pp. 85-87
    • Ogata, A.1    Umegaki, N.2    Katayama, I.3    Kumanogoh, A.4    Tanaka, T.5
  • 123
    • 84988017945 scopus 로고    scopus 로고
    • US National Library of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/show/NCT01490450 (2014).
    • (2014) ClinicalTrials.gov [online]
  • 124
    • 84865592373 scopus 로고    scopus 로고
    • Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A phase 2b randomized placebo-controlled dose-ranging study
    • Papp, K. A. et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 167, 668-677 (2012).
    • (2012) Br. J. Dermatol. , vol.167 , pp. 668-677
    • Papp, K.A.1
  • 125
    • 84879988459 scopus 로고    scopus 로고
    • A randomized phase 2a efficacy and safety trial on the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
    • Ports, W. C. et al. A randomized phase 2a efficacy and safety trial on the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br. J. Dermatol. 169, 137-145 (2013).
    • (2013) Br. J. Dermatol. , vol.169 , pp. 137-145
    • Ports, W.C.1
  • 126
    • 84988017945 scopus 로고    scopus 로고
    • US National Library of Medicine
    • US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01882439 (2014).
    • (2014) ClinicalTrials.gov [online]


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.